Managing toxicities associated with immune checkpoint inhibitors

被引：5

作者：

Park, Jiyeon Joy ^{[1
]}

Arafath, Syed ^{[2
]}

Kumar, Samir T. ^{[3
]}

Sharma, Roopali ^{[4
]}

Dixit, Deepali ^{[5
]}

机构：

[1] Rutgers State Univ, Ernest Mario Sch Pharm, Rutherford, NJ 08854 USA

[2] Presbyterian Weill Cornell Med Ctr Jama, Oncol Clin Pharm Specialist New York, Jamaica, NY USA

[3] SUNY Downstate Med Ctr, Internal Med Resident, Brooklyn, NY USA

[4] Touro Coll, Sch Pharm, Infect Dis Specialist, New York, NY USA

[5] Robert Wood Johnson Univ Hosp Piscataway, Rutgers & Clin Pharm Specialist Crit Care, Ernest Mario Sch Pharm, Piscataway, NJ USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2021年 / 34卷 / 06期

关键词：

immune checkpoint inhibitor; toxicity; cancer; immune-related adverse events; adverse reaction; overactivation; DERMATOLOGICAL ADVERSE EVENTS; CANCER-PATIENTS; IPILIMUMAB; MANAGEMENT; NIVOLUMAB; METAANALYSIS; PNEUMONITIS; ANTI-PD-1; BLOCKADE;

D O I：

10.1097/01.JAA.0000735760.65235.3c

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.

引用

页码：32 / 39

页数：8

共 50 条

[41] Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, Henry T.
Johnson, Douglas B.
LeBoeuf, Nicole R.
Zwerner, Jeffrey P.
Dewan, Anna K.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 956 - 966
[42] Dysautonomia associated with immune checkpoint inhibitors
Tezuka, Toshiki
Okuzumi, Shinichi
Nakashima, Chiho
Ide, Toshihiro
Imai, Shungo
Mitsuboshi, Satoru
Kuwahara, Yuki
Takizawa, Tsubasa
Seki, Morinobu
Minematsu, Naoto
Aragane, Naoko
Nakahara, Jin
Hori, Satoko
Nakane, Shunya
Suzuki, Shigeaki
JOURNAL OF NEUROLOGY, 2023, 270 (07) : 3413 - 3423
[43] Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, Bruno
Chan, Stephen L.
Meyer, Tim
Reig, Maria
El-Khoueiry, Anthony
Galle, Peter R.
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 320 - 341
[44] Management of pulmonary toxicity associated with immune checkpoint inhibitors
Delaunay, Myriam
Prevot, Gregoire
Collot, Samia
Guilleminault, Laurent
Didier, Alain
Mazieres, Julien
EUROPEAN RESPIRATORY REVIEW, 2019, 28 (154)
[45] Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Roberts, Kate
Culleton, Vanessa
Lwin, Zarnie
O'Byrne, Kenneth
Hughes, Brett G. M.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 277 - 288
[46] Managing Adverse Events With Immune Checkpoint Agents
Dadu, Ramona
Zobniw, Chrystia
Diab, Adi
CANCER JOURNAL, 2016, 22 (02) : 121 - 129
[47] Immune-related adverse events of immune checkpoint inhibitors: a brief review
Myers, G.
CURRENT ONCOLOGY, 2018, 25 (05) : 342 - 347
[48] Cardiothoracic complications of immune checkpoint inhibitors
Gosangi, Babina
Wang, Yifan
Rubinowitz, Ami N.
Kwan, Jennifer
Traube, Leah
Gange, Christopher
Bader, Anna S.
CLINICAL IMAGING, 2023, 102 : 98 - 108
[49] Infectious Complications of Immune Checkpoint Inhibitors
Abers, Michael S.
Lionakis, Michail S.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (02) : 235 - +
[50] Biomarkers for immune Checkpoint inhibitors in Melanoma
Kitano, Shigehisa
Nakayama, Takayuki
Yamashita, Makiko
FRONTIERS IN ONCOLOGY, 2018, 8

← 1 2 3 4 5 →